CC
ATRA icon

Centiva Capital’s Atara Biotherapeutics ATRA Stock Holding History

Centiva Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,403
Closed -$353K – 1672
2024
Q3 		$353K Sell
43,403
-96,847
-69% -$829K 0.01% 1478
2024
Q2 		$1.19M Buy
+140,250
New +$2.11M 0.02% 682
2023
Q3 		– Sell
-1,166
Closed -$46.9K – 1712
2023
Q2 		$46.9K Buy
+1,166
New +$65.9K ﹤0.01% 1508

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Centiva Capital's ATRA Position: Q4 2024 in Review

Centiva Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2024, closing a stake of 43,403 shares — an estimated $353K sold.

Centiva Capital first reported a position in ATRA in Q2 2023 and held it in 3 quarters. The position peaked at $1.19M in Q2 2024. 43 funds tracked by Wall St. Rank hold ATRA as of Q4 2024.

  • Centiva Capital reported no remaining Atara Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 43,403 Atara Biotherapeutics shares in Q4 2024, an estimated $353K.
  • Centiva Capital first reported a position in Atara Biotherapeutics in Q2 2023 and held it in 3 quarters.
  • Centiva Capital's Atara Biotherapeutics position peaked at $1.19M in Q2 2024.
  • 43 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.